Inside Diagnostics

Welcome to Inside Diagnostics, AstraZeneca’s bimonthly newsletter intended to update both clinicians and diagnosticians on biomarkers in Oncology. The Inside Diagnostics newsletter will cover topics ranging from newsflashes, congress summaries, novel biomarkers, educational videos on diagnostics, invitations for activities, etc. all focussed on the importance of targeted therapy.

Next to the newsletter you can participate in the targeted therapy discussions of our local oncology community on Linkedin.

Personalised Healthcare is an integral part of AstraZeneca’s approach to discovering and developing new medicines; we use diagnostics and biomarkers to target our treatments to patients most likely to benefit. AstraZeneca pioneered the concept of personalised healthcare as early as 1995 with the expression of Oestrogen Receptor in breast cancer as a selection for patients eligible for hormonotherapy. Today other examples include EGFR mutations in non small cell lung cancer, BRCA mutations in ovarian cancer and many more examples are to come in the next few years.

We believe that sharing scientific information and engaging with the medical community in an active way will support the development of diagnostic expertise and benefit patient therapy. Therefore we are delighted to present to you Inside Diagnostics and we sincerely hope you will become a passionate reader.

Rudy Hovelinck

Diagnostics Manager AstraZeneca

Other Inside Diagnostic Articles

About the author

Rudy Hovelinck

Diagnostics Manager AstraZeneca

rudy.hovelinck@astrazeneca.com

M. +32 (0) 476 22 58

Rudy Hovelinck obtained a scientific degree first in biochemistry at Ghent University and later in Molecular Biology at the ULB. Initially exploring the academic world in diverse fields as genetics, protein chemistry and virology, he soon realised that bridging scientific knowledge to the medical world was a more meaningful way of spending his professional life. This journey started in the field of pathology biomarker testing, introducing HER2 IHC and ISH testing for patient therapy selection and continued in the field of molecular oncology. Today at AstraZeneca he works as a diagnostics manager. In this role he is passionately contributing to the successful introduction of novel biomarkers and support current testing strategies for patient selection. In his own time he enjoys travelling with his family exploring the world and spending time close to nature. Specialties: Oncology, Anatomic Pathology, Biomarker Development, Medical Devices.